Literature DB >> 15001839

Cten mRNA expression is correlated with tumor progression in thymoma.

Hidefumi Sasaki1, Haruhiro Yukiue, Yoshihiro Kobayashi, Ichiro Fukai, Yoshitaka Fujii.   

Abstract

Cten is a recently isolated gene which has homology with tensin, suggesting that it is a focal adhesion molecule. Tensin family proteins play an important role in cell motility. We attempted to determine the influence of cten expression on clinicopathological features in patients with thymoma who had undergone surgery. Expression of cten messenger RNA was evaluated by reverse-transcription polymerase chain reaction in 45 thymoma samples using a LightCycler. There was no relationship between cten/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression and age, gender or pathological subtypes. However, cten/GAPDH expression was significantly higher in stage IV thymoma (5.463 +/- 7.730) when compared to stage I thymoma (0.905 +/- 0.811; p = 0.0187). Cten/GAPDH mRNA expression was correlated with evidence of tumor progression in thymoma. Consequently, cell motility or migration might play a role in progression of thymoma. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15001839     DOI: 10.1159/000076141

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  18 in total

1.  Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.

Authors:  Xuan Cao; Courtney Voss; Bing Zhao; Tomonori Kaneko; Shawn Shun-Cheng Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma.

Authors:  Jessica A Carter; Dariusz C Górecki; Charles A Mein; Börje Ljungberg; Sassan Hafizi
Journal:  Epigenetics       Date:  2013-05-24       Impact factor: 4.528

3.  Up-regulated cten by FGF2 contributes to FGF2-mediated cell migration.

Authors:  Shih-Ya Hung; Yi-Ping Shih; Michelle Chen; Su Hao Lo
Journal:  Mol Carcinog       Date:  2013-04-26       Impact factor: 4.784

4.  A Bayesian ensemble approach with a disease gene network predicts damaging effects of missense variants of human cancers.

Authors:  Hong-Hee Won; Jong-Won Kim; Doheon Lee
Journal:  Hum Genet       Date:  2012-08-21       Impact factor: 4.132

5.  CTEN prolongs signaling by EGFR through reducing its ligand-induced degradation.

Authors:  Shiao-Ya Hong; Yi-Ping Shih; Tianhong Li; Kermit L Carraway; Su Hao Lo
Journal:  Cancer Res       Date:  2013-06-17       Impact factor: 12.701

6.  Up-regulation of C-terminal tensin-like molecule promotes the tumorigenicity of colon cancer through beta-catenin.

Authors:  Yi-Chun Liao; Nien-Tsu Chen; Yi-Ping Shih; Ying Dong; Su Hao Lo
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

7.  Phylogenetic analysis, expression patterns, and transcriptional regulation of human CTEN gene.

Authors:  Nien-Tsu Chen; Yasuko Kuwabara; Christopher Conley; Yi-Chun Liao; Shiao-Ya Hong; Michelle Chen; Yi-Ping Shih; Hong-Wu Chen; Fushing Hsieh; Su Hao Lo
Journal:  Gene       Date:  2013-03-14       Impact factor: 3.688

Review 8.  C-terminal tensin-like (CTEN): a promising biomarker and target for cancer.

Authors:  Su Hao Lo
Journal:  Int J Biochem Cell Biol       Date:  2014-04-13       Impact factor: 5.085

9.  Clinical Significance of Tensin 4 Gene Expression in Patients with Gastric Cancer.

Authors:  Sho Sawazaki; Takashi Oshima; Kentaro Sakamaki; Toru Aoyama; Tsutomu Sato; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Toshio Imada; Munetaka Masuda
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

10.  Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas.

Authors:  Saleh Al-Ghamdi; Abdulkader Albasri; Julien Cachat; Salih Ibrahem; Belal A Muhammad; Darryl Jackson; Abdolrahman S Nateri; Karin B Kindle; Mohammad Ilyas
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.